Evotec SE has successfully achieved a third milestone in its diabetes research alliance with Sanofi (TargetBCD), resulting in a €3 million payment to Evotec. Evotec met pre-agreed critical criteria within the beta cell replacement therapy program. The goal of the collaboration is to develop a beta cell replacement therapy for people with diabetes based on beta cells derived from human induced pluripotent stem cells. Dr. Cord Dohrmann, chief scientific officer of Evotec, said, “We are...